Century Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Century Therapeutics, Inc. (IPSC) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-12
- Century Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.16M.
- Century Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $62.00K.
- Century Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$1.32M.
- Century Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$585.00K, a 178.95% decline year-over-year.
- Century Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$2.34M.
- Century Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$543.00K.
- Century Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$667.00K.
- Century Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$1.03M, a 132.31% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.22M 10-Q · filed 2026-08-12 | -$104.00K derived: sum of 3 quarters · filed 2026-08-12 | -$689.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $62.00K 10-Q · filed 2026-05-13 | -$1.26M derived: sum of 2 quarters · filed 2026-05-13 | -$1.84M derived: sum of 3 quarters · filed 2026-05-13 | -$1.99M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$1.91M derived: sum of 2 quarters · filed 2026-03-12 | -$2.05M derived: sum of 3 quarters · filed 2026-08-12 | -$2.34M 10-K · filed 2026-03-12 | |
| 2025-09-30 | -$585.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$732.00K derived: sum of 2 quarters · filed 2026-08-12 | -$1.02M 10-Q · filed 2025-11-13 | -$4.43M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$147.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$436.00K 10-Q · filed 2026-08-12 | -$3.84M derived: sum of 3 quarters · filed 2026-08-12 | -$3.10M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$289.00K 10-Q · filed 2026-05-13 | -$3.69M derived: sum of 2 quarters · filed 2026-05-13 | -$2.95M derived: sum of 3 quarters · filed 2026-05-13 | -$4.23M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$3.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$2.67M derived: sum of 2 quarters · filed 2026-03-12 | -$3.94M derived: sum of 3 quarters · filed 2026-03-12 | -$543.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $741.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$532.00K derived: sum of 2 quarters · filed 2025-11-13 | $2.86M 10-Q · filed 2025-11-13 | $2.60M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.12M 10-Q · filed 2025-08-14 | $1.86M derived: sum of 3 quarters · filed 2025-08-14 | $1.19M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $3.40M 10-Q · filed 2025-05-15 | $3.14M derived: sum of 2 quarters · filed 2025-05-15 | $2.46M derived: sum of 3 quarters · filed 2025-05-15 | $2.57M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$935.00K derived: sum of 2 quarters · filed 2025-03-19 | -$827.00K derived: sum of 3 quarters · filed 2025-03-19 | -$667.00K 10-K · filed 2025-03-19 | |
| 2023-09-30 | -$676.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$568.00K derived: sum of 2 quarters · filed 2024-11-05 | -$408.00K 10-Q · filed 2024-11-05 | -$1.83M derived: sum of 4 quarters · filed 2024-11-05 | |
| 2023-06-30 | $108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $268.00K 10-Q · filed 2024-08-08 | -$1.16M derived: sum of 3 quarters · filed 2024-08-08 | -$521.00K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $160.00K 10-Q · filed 2024-05-09 | -$1.26M derived: sum of 2 quarters · filed 2024-05-09 | -$629.00K derived: sum of 3 quarters · filed 2024-05-09 | $165.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$789.00K derived: sum of 2 quarters · filed 2024-03-14 | $5.00K derived: sum of 3 quarters · filed 2024-03-14 | -$1.03M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $634.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.43M derived: sum of 2 quarters · filed 2023-11-09 | $395.00K 10-Q · filed 2023-11-09 | $582.00K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $794.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$239.00K 10-Q · filed 2023-08-09 | -$241.00K 10-Q · filed 2022-08-11 | -$52.00K derived: sum of 3 quarters · filed 2023-08-09 | $446.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$1.03M 10-Q · filed 2023-05-11 | -$846.00K derived: sum of 2 quarters · filed 2023-05-11 | -$348.00K derived: sum of 3 quarters · filed 2023-05-11 | $2.32M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $685.00K derived: sum of 2 quarters · filed 2023-03-16 | $3.35M derived: sum of 3 quarters · filed 2023-03-16 | $3.18M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $498.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.17M derived: sum of 2 quarters · filed 2022-11-10 | $3.00M 10-Q · filed 2022-11-10 | $3.98M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.50M 10-Q · filed 2022-08-11 | $3.48M derived: sum of 3 quarters · filed 2022-08-11 | $4.06M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$173.00K 10-Q · filed 2022-05-16 | $809.00K derived: sum of 2 quarters · filed 2022-05-16 | $1.39M derived: sum of 3 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $982.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.56M derived: sum of 2 quarters · filed 2022-03-17 | $203.00K 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $581.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$779.00K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | -$1.36M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |